한글목차

오시머티닙 의약품 시장 규모는 최근 급성장하고 있습니다. 2025년 77억 5,000만 달러에서 2026년에는 89억 4,000만 달러에 이르고, CAGR 15.3%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 비소세포폐암(NSCLC) 발생률 증가, EGFR 변이 검사 증가, 1세대 TKI 대비 임상적 우위, 주요 시장에서의 규제 당국의 승인, 암 치료 비용 증가에 기인하는 것으로 보입니다.

오시머티닙 약품 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 162억 5,000만 달러에 이르고, CAGR은 16.1%를 나타낼 전망입니다. 예측 기간 동안의 성장은 정밀 종양학 프로그램 확대, 신흥국에서의 진단율 향상, 차세대 EGFR 억제제 개발, 급여 범위 확대, 신규 적응증에 대한 임상시험의 지속 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 EGFR 1차 치료제로서의 사용 확대, 전이성 비소세포폐암 치료에서의 사용 증가, 경구용 표적치료제 선호도 증가, 병용요법 연구 증가, 1일 1회 투여로 인한 환자 순응도 개선 등이 있습니다.

폐암 발생률 증가는 향후 몇 년 동안 오시머티닙 약물 시장의 성장을 가속할 것으로 예측됩니다. 폐암은 폐 조직, 주로 기도를 덮고 있는 세포에 발생하는 암의 일종입니다. 오시머티닙은 암세포의 증식과 확산에 관여하는 특정 단백질을 표적으로 하는 폐암 치료제로 사용됩니다. 예를 들어, 2023년 1월 미국암협회(American Cancer Society)의 통계에 따르면, 2022년 미국 내 폐암 및 기관지암 신규 환자 수는 23만 6,740명, 2023년 23만 8,340명으로 추산됩니다. 한편, 사망자 수는 2022년 13만 180명, 2023년 12만 7,070명으로 추산되고 있습니다. 따라서 폐암 발생률 증가가 오시머티닙 치료제 시장의 성장을 견인하고 있습니다.

향후 폐암 치료 및 치료 개선을 위한 체계적인 노력 증가는 오시머티닙 치료제 시장의 성장을 가속할 것으로 예측됩니다. 이러한 조직적 노력에는 폐암 진단을 받은 개인의 치료 접근성, 경제성, 질을 향상시키기 위해 고안된 정책, 자금 지원, 프로그램 등이 포함됩니다. 많은 조직들이 보다 효과적인 치료를 위해 오시머티닙 사용을 최적화하는 전략을 시행하고 있습니다. 예를 들어, 2024년 5월 호주 정부 기관인 보건 및 노인복지부는 '전국 폐암 검진 프로그램(NLCSP)'을 시행했습니다. 이 프로그램은 저선량 컴퓨터 단층촬영(LDCT) 스캔을 이용한 폐암 조기 발견을 목적으로 하며, 특히 흡연력이 많은 50세에서 80세 사이의 고위험군을 대상으로 합니다. 따라서 이러한 체계적인 폐암 관리 및 치료 개선 노력이 오시머티닙 치료제 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Osimertinib is a medication used to treat non-small cell lung cancer (NSCLC) in patients with specific abnormal epidermal growth factor receptor (EGFR) genes. It is a kinase inhibitor that works by blocking the activity of the abnormal protein that signals cancer cells to grow and multiply.

The main types of osimertinib drugs are 40 mg and 80 mg. The 40 mg refers to the dosage strength of the osimertinib tablet. These drugs are distributed through various channels, including hospital pharmacies, drugstores, retail pharmacies, and online pharmacies, for the treatment of locally advanced NSCLC, metastatic NSCLC, and other indications.

Tariffs have created moderate challenges for the osimertinib drugs market by increasing the cost of active pharmaceutical ingredients, specialty chemicals, and cross-border manufacturing inputs used in targeted cancer therapies. These impacts are most visible in branded drug supply chains and hospital pharmacy distribution channels, with asia-pacific and europe being more affected due to their dependence on imported pharmaceutical components. Tariff-related cost pressures may influence pricing and reimbursement negotiations, particularly in cost-sensitive healthcare systems. However, tariffs are also encouraging pharmaceutical companies to localize production, strengthen regional manufacturing hubs, and optimize supply chains, which may improve long-term resilience of the market.

The osimertinib drugs market research report is one of a series of new reports from The Business Research Company that provides osimertinib drugs market statistics, including osimertinib drugs industry global market size, regional shares, competitors with a osimertinib drugs market share, detailed osimertinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osimertinib drugs industry. This osimertinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osimertinib drugs market size has grown rapidly in recent years. It will grow from $7.75 billion in 2025 to $8.94 billion in 2026 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to rising incidence of nsclc, increased egfr mutation testing, clinical success over first-generation tkis, regulatory approvals in major markets, growing oncology healthcare spending.

The osimertinib drugs market size is expected to see rapid growth in the next few years. It will grow to $16.25 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expansion of precision oncology programs, increasing diagnosis rates in emerging economies, development of next-generation egfr inhibitors, broader reimbursement coverage, ongoing clinical trials for new indications. Major trends in the forecast period include expanded use as first-line egfr therapy, rising adoption in metastatic nsclc treatment, growing preference for oral targeted therapies, increasing combination therapy research, improved patient compliance through once-daily dosing.

The rising incidence of lung cancer is expected to propel the growth of the osimertinib drug market in the coming years. Lung cancer is a type of cancer that originates in lung tissues, primarily in the cells lining the airways. Osimertinib is used as a therapeutic option for lung cancer, targeting specific proteins involved in the growth and spread of cancer cells. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organization, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the rising incidence of lung cancer is driving the growth of the osimertinib drug market.

The increasing initiatives from organizations to improve lung cancer care and treatment are expected to drive the growth of the osimertinib drug market going forward. These organizational initiatives include policies, funding, and programs designed to enhance accessibility, affordability, and quality of care for individuals diagnosed with lung cancer. Many organizations are implementing strategies to optimize the use of osimertinib for more effective treatment. For instance, in May 2024, the Australian Department of Health and Aged Care, an Australia-based government agency, implemented the National Lung Cancer Screening Program (NLCSP). This program aims to enable early detection of lung cancer using low-dose computed tomography (LDCT) scans, specifically targeting high-risk individuals aged 50 to 80 with a significant smoking history. Therefore, these organizational initiatives to improve lung cancer care and treatment are driving the growth of the osimertinib drug market.

Major companies in the osimertinib drugs market are focusing on targeted therapies to enhance outcomes for patients with non-small cell lung cancer (NSCLC), particularly those with EGFR mutations, aiming to improve treatment efficacy and patient quality of life. These companies are also investing in clinical trials and research collaborations to expand osimertinib's indications and explore its use in combination with other therapies for broader patient benefits. For instance, in September 2024, AstraZeneca Pharmaceuticals LP, a US-based pharmaceutical company, launched osimertinib (Tagrisso) for adults with locally advanced, unresectable NSCLC with specific EGFR mutations, approved by the FDA. This approval followed clinical trials demonstrating significant improvements in progression-free survival compared to placebo.

Major companies operating in the osimertinib drugs market are AstraZeneca plc, Dr. Reddy's Laboratories Ltd., Cipla Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Beacon Pharmaceutical Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Hetero Drugs Ltd., Accord Healthcare Limited, Dolphin Pharmaceutical Limited, Radiant Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., Eskayef Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Natco Pharma Limited, Alkem Laboratories Ltd.

North America was the largest region in the osimertinib drugs market in 2025. The regions covered in the osimertinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osimertinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osimertinib drugs market consists of sales of tagrisso, osi-TKI, and osimertinib mesylate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osimertinib Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses osimertinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osimertinib drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The osimertinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 40 mg; 80 mg
• 2) By Distribution Channel: Hospital Pharmacy; Drug Store And Retail Pharmacy; Online Pharmacy
• 3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC); Other Applications
• Subsegments:
• 1) By 40 mg: Maintenance Therapy in Tolerability-Sensitive Patients; Dose Adjustment for Drug-Drug Interactions
• 2) By 80 mg: First-Line Treatment for EGFR-Mutated NSCLC; Second-Line Treatment for T790M-Positive NSCLC
• Companies Mentioned: AstraZeneca plc; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Zydus Lifesciences Limited; Sun Pharmaceutical Industries Ltd.; Alembic Pharmaceuticals Limited; Aristo Pharmaceuticals Private Limited; Incepta Pharmaceuticals Ltd.; Beacon Pharmaceutical Limited; Drug International Limited; MSN Laboratories Pvt Ltd.; Hetero Drugs Ltd.; Accord Healthcare Limited; Dolphin Pharmaceutical Limited; Radiant Pharmaceuticals Ltd.; Beximco Pharmaceuticals Ltd.; Eskayef Pharmaceuticals Ltd.; Intas Pharmaceuticals Ltd.; Natco Pharma Limited; Alkem Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Osimertinib Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Osimertinib Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Osimertinib Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Osimertinib Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expanded Use As First-Line Egfr Therapy
  • 4.2.2 Rising Adoption In Metastatic Nsclc Treatment
  • 4.2.3 Growing Preference For Oral Targeted Therapies
  • 4.2.4 Increasing Combination Therapy Research
  • 4.2.5 Improved Patient Compliance Through Once-Daily Dosing

5. Osimertinib Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Specialty Clinics
• 5.3 Cancer Research Institutes
• 5.4 Academic Medical Centers
• 5.5 Ambulatory Care Centers

6. Osimertinib Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Osimertinib Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Osimertinib Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Osimertinib Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Osimertinib Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Osimertinib Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Osimertinib Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Osimertinib Drugs Market Segmentation

• 9.1. Global Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 40 mg, 80 mg
• 9.2. Global Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy
• 9.3. Global Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Other Applications
• 9.4. Global Osimertinib Drugs Market, Sub-Segmentation Of 40 mg, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Maintenance Therapy in Tolerability-Sensitive Patients, Dose Adjustment for Drug-Drug Interactions
• 9.5. Global Osimertinib Drugs Market, Sub-Segmentation Of 80 mg, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• First-Line Treatment for EGFR-Mutated NSCLC, Second-Line Treatment for T790M-Positive NSCLC

10. Osimertinib Drugs Market Regional And Country Analysis

• 10.1. Global Osimertinib Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Osimertinib Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Osimertinib Drugs Market

• 11.1. Asia-Pacific Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Osimertinib Drugs Market

• 12.1. China Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Osimertinib Drugs Market

• 13.1. India Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Osimertinib Drugs Market

• 14.1. Japan Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Osimertinib Drugs Market

• 15.1. Australia Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Osimertinib Drugs Market

• 16.1. Indonesia Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Osimertinib Drugs Market

• 17.1. South Korea Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Osimertinib Drugs Market

• 18.1. Taiwan Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Osimertinib Drugs Market

• 19.1. South East Asia Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Osimertinib Drugs Market

• 20.1. Western Europe Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Osimertinib Drugs Market

• 21.1. UK Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Osimertinib Drugs Market

• 22.1. Germany Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Osimertinib Drugs Market

• 23.1. France Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Osimertinib Drugs Market

• 24.1. Italy Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Osimertinib Drugs Market

• 25.1. Spain Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Osimertinib Drugs Market

• 26.1. Eastern Europe Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Osimertinib Drugs Market

• 27.1. Russia Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Osimertinib Drugs Market

• 28.1. North America Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Osimertinib Drugs Market

• 29.1. USA Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Osimertinib Drugs Market

• 30.1. Canada Osimertinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Osimertinib Drugs Market

• 31.1. South America Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Osimertinib Drugs Market

• 32.1. Brazil Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Osimertinib Drugs Market

• 33.1. Middle East Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Osimertinib Drugs Market

• 34.1. Africa Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Osimertinib Drugs Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Osimertinib Drugs Market Regulatory and Investment Landscape

36. Osimertinib Drugs Market Competitive Landscape And Company Profiles

• 36.1. Osimertinib Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Osimertinib Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Osimertinib Drugs Market Company Profiles
  • 36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Zydus Lifesciences Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Osimertinib Drugs Market Other Major And Innovative Companies

• Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Beacon Pharmaceutical Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Hetero Drugs Ltd., Accord Healthcare Limited, Dolphin Pharmaceutical Limited, Radiant Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., Eskayef Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Natco Pharma Limited, Alkem Laboratories Ltd.

38. Global Osimertinib Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Osimertinib Drugs Market

40. Osimertinib Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Osimertinib Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Osimertinib Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Osimertinib Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer